mesalazine
Small moleculeexperimental
Mesalazine, also known as mesalamine or 5-aminosalicylic acid (5-ASA), is a medication used to treat inflammatory bowel disease, including ulcerative colitis and Crohn's disease. It is generally used for mildly to moderately severe disease. It is taken by mouth or rectally. The formulations which are taken by mouth appear to be similarly-effective. — Wikipedia
Clinical trial activity
17 trials · 16 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
8
Phase 3
4
Phase 4
2
Earliest trial started Oct 1, 2006 (NCT00573469)
Timeline
Indications
Approved for
Mechanism of action
- Unspecified targetUnclear
Unclear
Chemistry & pharmacology
Loading structure…
SMILES
Nc1ccc(O)c(C(=O)O)c1- Mol. weight
- 153.14 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral, Topical
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
Yes
Sources
- WikipediaMesalazine ↗
- ChEMBLCHEMBL704 ↗
Also known as
- d9421
- d9421-c
- mesalazine
- mesalazine
- mesalazine
- mesalazine
- mesalazine
- tp05
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06176560 | Phase 3 | Mar 31, 2024 | Faes Farma, S.A. |
| NCT06201793 | Phase 2 | Jan 22, 2024 | Tanta University |
| NCT05912712 | Phase 1 | Jul 1, 2023 | People's Liberation Army of China |
| NCT05387083 | Phase 2 | Jul 29, 2022 | Tarsus Pharmaceuticals, Tufts University |
| NCT05205603 | Phase 4 | Jan 15, 2022 | Sun Yat-Sen University |
| NCT05138796 | Phase 1 | May 6, 2021 | Tarsus Pharmaceuticals |
| NCT05538026 | N/A | Sep 1, 2020 | Bogomolets National Medical University, Government of Ukraine |
| NCT04133194 | Phase 4 | Nov 1, 2019 | University of Copenhagen |
| NCT03917095 | N/A | May 15, 2019 | Nanjing Medical University |
| NCT03412682 | Phase 3 | Mar 2, 2018 | Ferring |
| NCT03441893 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2015 | Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan |
| NCT02306798 | Phase 1 | Sep 1, 2013 | Tillotts Pharma |
| NCT01903252 | Phase 3 | Jul 1, 2013 | Robarts Clinical Trials, Tillotts Pharma |
| NCT02306785 | Phase 1 | Oct 1, 2012 | Tillotts Pharma |
| NCT01514240 | Phase 3 | Feb 1, 2012 | AstraZeneca, Keio University |
| NCT02306772 | Phase 1 | Dec 1, 2011 | Tillotts Pharma |
| NCT00573469 | Phase 2 | Oct 1, 2006 | AstraZeneca |
Showing 17 of 17 trials
Page 1 / 1
Organizations
Research & Development (16)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Tillotts Pharma | For profit | 4 | 4 | 2 | 2011 |
| AstraZeneca | For profit | 2 | 2 | 2 | 2006 |
| Tarsus Pharmaceuticals | For profit | 2 | 2 | 2 | 2021 |
| Bogomolets National Medical University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Faes Farma, S.A. | For profit | 1 | 1 | 1 | 2024 |
| Ferring | For profit | 1 | 1 | 1 | 2018 |
| Government of Ukraine | Government | 1 | 0 | 1 | 2020 |
| Keio University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Nanjing Medical University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| People's Liberation Army of China | Government | 1 | 1 | 1 | 2023 |
| Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Robarts Clinical Trials | For profit | 1 | 0 | 1 | 2013 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Tanta University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Tufts University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Copenhagen | Academic/Hospital | 1 | 1 | 1 | 2019 |
16 organizations
Page 1 / 1